Clinical Trials for NGM Biopharmaceuticals

Explore 4 clinical trials worldwide

Showing 1-4 of 4 trials

Active filters:Status: Recruiting, Active, not recruiting, Enrolling by invitation, Not yet recruitingSponsor: NGM Biopharmaceuticals

Clinical Trials (4)

NCT07033026
An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.
PHASE2Recruiting
136 participants
Started: Jun 30, 2025 · Completed: Dec 31, 2027
3 conditions1 sponsor1 location
NCT05311618
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
PHASE1Active, not recruiting
71 participants
Started: May 11, 2022 · Completed: Jun 30, 2025
16 conditions2 sponsors6 locations
NCT05215574
Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors
PHASE1Active, not recruiting
130 participants
Started: Mar 31, 2022 · Completed: Mar 31, 2026
16 conditions2 sponsors9 locations
NCT04913337
Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies
PHASE1/PHASE2Active, not recruiting
179 participants
Started: Jun 9, 2021 · Completed: Jul 31, 2025
15 conditions2 sponsors27 locations